首页 | 本学科首页   官方微博 | 高级检索  
检索        

吡非尼酮对实验性大鼠肝纤维化的作用
引用本文:杜磊,王昌源,张立华,谭炳芹.吡非尼酮对实验性大鼠肝纤维化的作用[J].山东大学学报(医学版),2009,47(11):50-54.
作者姓名:杜磊  王昌源  张立华  谭炳芹
作者单位:山东大学医学院 济南市传染病医院, 济南 250021
摘    要:目的研究吡非尼酮(PFD)对实验性大鼠的抗肝纤维化作用。方法45只雄性Wistar大鼠随机均分为3组。模型组腹腔注射1%二甲基亚硝胺(DMN)10?mg/(kg·d),每周连续3d,共4周,制作肝纤维化模型;干预组除应用DMN外,同时给予PFD 500?mg/(kg·d)灌胃,1次/d,共4周;模型组及正常组以等体积生理盐水灌胃作对照。4周试验结束时进行组织学检查、电镜观察、血清肝纤维化指标、肝功能及转化生长因子 β1(TGF β1)检测。结果与模型组相比,干预组大鼠体质量下降较少(P<0.05)、肝脾肿大较轻(P<0.05),血清透明质酸、层粘连蛋白和Ⅳ型胶原浓度均明显低于模型组(P<0.05);干预组血清谷丙转氨酶、谷草转氨酶、总胆红素及TGF β1含量与模型组相比明显降低(P<0.001);MASSON染色显示,干预组肝脏纤维化及炎症反应明显减轻,无明显假小叶;透射电镜观察证实干预组大鼠肝细胞损伤明显减轻,肝窦及Disse腔内胶原纤维沉积明显减少。结论PFD对实验性大鼠肝纤维化模型具有明显的抗肝纤维化作用,其机制可能与抑制TGF β1的产生有关,PFD有可能用于肝脏疾病的抗纤维化治疗。

关 键 词:吡非尼酮  纤维化,肝  大鼠,Wistar  转化生长因子  β1  
收稿时间:2008-12-21

Effects of pirfenidone on liver fibrosis in rats
DU Lei,WANG Chang-yuan,ZHANG Li-hua,TAN Bing-qin.Effects of pirfenidone on liver fibrosis in rats[J].Journal of Shandong University:Health Sciences,2009,47(11):50-54.
Authors:DU Lei  WANG Chang-yuan  ZHANG Li-hua  TAN Bing-qin
Institution:Jinan Infectious Disease Hospital, School of Medicine, Shandong University, Jinan 250021, China
Abstract:Objective To investigate the effects of pirfenidone (PFD) on liver fibrosis in experimental rats. Methods Forty-five male Wistar rats were randomly divided into three groups. The model group was intraperitoneally injected with 1% dimeth-ylnitrosamine (DMN) 10 mg/kg per day for the first three days of each week for 4 weeks. The intervention group was orally given PFD 500 mg/kg every day for 4 weeks starting on the day of the first injection of DMN. The control group was given normal sodi-tun. Rats were killed at the end of the 4th week, and the livers and spleens were removed. Blood samples were obtained immedi-ately before rats were killed. Liver histological and ultramicroscopic changes were observed, serum indices of liver fibrosis and liver function were examined, and the level of transforming growth factor β1 (TGF-β1) was determined. Results Compared with the model group, the intervention group had a higher bodyweight(P<0.05) but splenohepatomegaha was less(P<0.05). Se-arm levels of hyahronic acid, laminin and type Ⅳ collagen of the intervention group were significantly lower than those of the model group(P<0.05), however serum levels of alanine aminotransferase(ALT), aspartate aminotransferase (AST), total bil-irubin(TBIL) and TGF-β1 were significandy higher than those of the model group(P<0.001). Masson trichrome staining showed that the intervention group had mild bridging fibrosis and less lymphocyte infiltration. No typical pseudo-lobuh was found. Trans-mission electron microscopy demonswated that hepatic cell injury in the intervention group was significantly less than that in the model group and slight collagen fibers were observed in the sinus hepaticus and Disse space. Conchisions PFD has a significant anti-fibresis effect in experimental rats, which was presumably caused by inhibiting the production of TGF-β1.
Keywords:Pirfenidone  Fibrosis  liver  Wistar rats
本文献已被 万方数据 等数据库收录!
点击此处可从《山东大学学报(医学版)》浏览原始摘要信息
点击此处可从《山东大学学报(医学版)》下载免费的PDF全文
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号